Survey Assessing the Environment for Developing Treatments for Rare Diseases
Back
In partnership with the Save Rare Treatments Task Force, CLS is conducting a survey of our membership to gather feedback from across the life sciences ecosystem about key impacts of the narrow Orphan Drug Exclusion in the Medicare Drug Price Negotiation Program (MDPNP) and its impact on rare disease research and innovation. The results from the survey will be used to help bolster the advocacy efforts of CLS and our partner organizations. CLS will deidentify and aggregate all survey responses. If you are interested in preserving incentives for medical innovation to treat rare diseases, please consider participating in the survey.